MSK.P-035 PATENT APPLICATION

CLAIMS

 $\int_{0}^{\infty} \int_{0}^{2}$

A recombinant polynucleotide encoding a fusion protein comprising the variable region of the light chain of a selected antibody linked to the variable region of the heavy chain of the selected antibody, the signaling domain of human CD28 receptor and a transmembrane domain.

- 1 2
- The recombinant polynucleotide of claim 1, wherein the transmembrane domain to the human CD28 transmembrane domain.
- 口₁ 四2
- 3. The recombinant polynucleotide of claim 1, wherein the selected antibody is an anti- G_{D2} antibody.

1

2

1

2

- 4. The recombinant polynucleotide of claim 3, further comprising a region encoding a suicide gene.
- 5. The recombinant polynucleotide of claim 4, wherein the suicide gene encodes thymidine kinase.
- 6. The recombinant polynucleotide of claim 1, further comprising a-region -encoding a suicide gene.
- 7. The recombinant polynucleotide of claim 6, wherein the suicide gene encodes thymidine kinase.

MSK.P-035 PATENT APPLICATION

	8.	A recombinant peptide comprising the variable region of the light chain of a
selected antib	oody lin	ked to the variable region of the selected antibody, the signaling domain of
the human C	D28 rec	ceptor and a transmembrane domain.
	9.	The recombinant peptide of claim 8, wherein the transmembrane domain to
the human C	D28 tra	nsmembrane domain.
	10.	The peptide according to claim 9, wherein the selected antibody is an anti-
G _{D2} antibody		
	,	
	J. H.	T cells expressing a recombinant peptide comprising the variable region of
the light chai	n of sel	ected antibody linked to the variable region of the heavy chain of the selected
antibody and	to the s	signaling domain of the human CD28 receptor and a transmembrane domain.
	12.	T cells of claim 11, wherein the transmembrane domain to the human
CD28 transm	embran	ne domain.
	13.	T cells according to claim 11, wherein the selected antibody is an anti- G_{D2}
antibody.		
	14.	T cells according to claim 13, wherein the T cells further express a suicide
gene.		
	15.	T cells according to claim 14, wherein the suicide gene encodes thymidine
kinase.		

MSK.P-035 PATENT APPLICATION

1	16. A method for inducing in a host an immune response to tumor cells		
2	expressing a surface antigen comprising the steps of		
3	(a) transducing T cells to introduce an expressible recombinant polynucleotide		
4	encoding a fusion protein comprising the variable region of the light chain of an antibody against		
5	the surface antigen, linked to variable region of the heavy chain of an antibody against the surface		
6	antigen, the signaling domain of human CD28 receptor and a transmembrane domain; and		
7	(b) introducing transduced T cells expressing the recombinant polynucleotide		
8	into the host.		
1	17. The method according to claim 16, wherein the transmembrane domain to		
C2 Q + 1 C2 + 2 + 3	the human CD28 transmembrane domain.		
	18. The method of claim 16, wherein the tumor cells express G_{D2} as a surface		
J 2	antigen, and wherein the fusion protein includes the light chain and the heavy chain of an antibody		
‡ 3	against G_{D2} .		
	19. The method according to claim 18, wherein the expressible polynucleotide		
	further encodes a suicide gene.		
1	20. The method according to claim 19, wherein the expressible polynucleotide		
2	further encodes a suicide gene.		